NMI Holdings, Inc. Announces Proposed Public Offering of Common Stock
Feb 26, 2018 21:16 pm UTC| Business
EMERYVILLE, Calif., Feb. 26, 2018 -- NMI Holdings, Inc. (Nasdaq:NMIH) (the “Company”) today announced it has commenced an underwritten registered public offering of 3,700,000 shares of its Class A common stock, par...
ARMOUR Residential REIT, Inc. Announces March 2018 Dividend of $0.19 Per Common Share
Feb 26, 2018 21:15 pm UTC| Business
VERO BEACH, Florida, Feb. 26, 2018 -- ARMOUR Residential REIT, Inc. (NYSE: ARR, ARR PrA and ARR PrB) (“ARMOUR” or the “Company”) today announced the March 2018 cash dividend for the Company’s Common Stock, which...
Feb 26, 2018 21:15 pm UTC| Business
GAITHERSBURG, Md. and LYON, France, Feb. 26, 2018 -- Emergent BioSolutions Inc. (NYSE:EBS) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the...
Willis Towers Watson Increases Regular Quarterly Dividend and Share Repurchase Program
Feb 26, 2018 21:15 pm UTC| Business
ARLINGTON, Va. and LONDON, Feb. 26, 2018 -- Willis Towers Watson (NASDAQ:WLTW), a leading global advisory, broking and solutions company, announced that its Board of Directors approved a regular quarterly cash dividend...
Gold Resource Corporation Declares February Monthly Dividend
Feb 26, 2018 21:15 pm UTC| Business
COLORADO SPRINGS, CO, Feb. 26, 2018 -- Gold Resource Corporation (NYSE American: GORO) (the “Company”) declares its monthly instituted dividend of 1/6 of a cent per common share for February 2018 payable on March 23,...
Feb 26, 2018 21:15 pm UTC| Business
MONTCLAIR, N.J., Feb. 26, 2018 -- 180 Degree Capital Corp. (NASDAQ:TURN) (“180” and the “Company”), today reported its financial results as of December 31, 2017. Key results for the quarter and year include: Q4...
Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
Feb 26, 2018 21:15 pm UTC| Business
– Strong cash position to support eptinezumab development through approval and commercial launch – – Recently reported pivotal PROMISE 2 top-line data in chronic migraine demonstrates eptinezumab significantly...